Pipette adding blue fluid test tube close up | © Stockphoto/Chet Chaimangkhalayon
Where Science, Innovation and Quality Meet
Germany is the world’s leading medical biotech nation behind the US. The industry’s strength comes from the presence of long-established and start-up companies alike. Industry, government, and the research sector are pulling in one direction to build on the thriving sector’s already strong market foundations. With the largest amount of biotech companies in Europe, world-class research infrastructure, and internationally renowned scientists, Germany has firmly established itself as an international medical biotechnology hub.
Fact Sheet: Biotechnology Clusters in Germany | © GTAI
Biotechnology Clusters in Germany
In 2015 the total number of biotechnology companies in Germany increased to 726, employing more than 39,000 people – a new high. More
|7.02 bn (2012)|
9.8% increase in 2012
53.1% pre-clinical stage or technology platform.
|R&D Expenditure||approx. 10.6% of annual turnover in 2012, 749 ml 2012|
|Number of Employees||36.000|
|Number of Companies||385|
Science and industry need to work itogether closely in order for innovations to be commercialized successfully. German bioclusters are proving to be important new technology impulse givers in this respect.
Over the past three decades, Germany’s 36 biotechnology clusters - known as BioRegions - have developed into Europe’s leading research and development hubs. Each region specializes in particular areas and facilitates the collaboration between universities, R&D institutes and private sector companies. Investors benefit from easy access to networks and funding for research projects. The BioRegions also include technology parks tailored to the specific needs of biotechnology companies. These centers offer an ideal infrastructure including lab space and clean rooms as well as a range of services for both start-ups and long-established companies.
In 2012 the Biotechnology Cluster for Individualized Immune Intervention (CI3) in Mainz was granted EUR 40 million to help bring biotechnological innovations to industrial maturity as part of the Federal Ministry of Education and Research’s Leading Edge Cluster Competition. Another EUR 40 million will be provided by the partners involved in the cluster projects. . A permanent and cross-sectoral working group has been installed to actively support the authorities developing the regulatory system as a critical element for commercializing the innovative output of the cluster.
Growing Biopharmaceuticals Market
Five hundred seventy eight biopharmaceuticals are currently in clinical development in Germany. Of these, monoclonal antibodies - with 314 projects in total – account for the main area of focus. The clinical development pipeline has achieved its highest growth levels in phases I and II specifically; an indicator which demonstrates accelerated progress in both the discovery as well as the development of drug candidates.
Growth Driver: Molecular Diagnostics
The five “-omics” are driving the global and German pharmaceutical industry today: genomics, epigenomics, metabolomics, proteomics, and transcriptomics are the means for prognostic diagnoses for patient susceptibility to disease as well as therapeutics. Molecular diagnostics (Dx) is the most promising in vitro diagnostics subsegment in Germany, with the country accounting for the largest IVD market in Europe and second only to the US globally. Molecular Dx already enjoys more than 10 percent share of the entire German diagnostics market and boasts a growth rate more than twice that of the entire IVD market as such.
Growth Driver: Biopharmaceuticals
In 2012, the German biopharmaceuticals market recorded sales of more than EUR 7 billion – an increase of almost 10 percent on the previous year. This is equivalent to 21 percent of the total pharmaceutical market. With a historical reputation as the world’s pharmacy, Germany’s classical pharma sector enjoys market stability. The nature industry sector is comprised of 899 pharmaceutical companies, employing a one hundred thousand strong workforce. In contrast to biopharma it shows a lower growth potential, having grown only two percent in 2011 but still reaching the significantly higher market volume of EUR 32.2 billion.